Report cover image

Advanced ovarian cancer - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 210 Pages
SKU # DEL18679192

Description

Advanced ovarian cancer - Pipeline Insight, 2024



DelveInsight’s, “Advanced ovarian cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced ovarian cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Advanced ovarian cancer Understanding

Advanced ovarian cancer: Overview

Advanced ovarian cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have advanced ovarian cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of the cancer. Chemotherapy, surgery and targeted cancer drugs are all treatments for advanced ovarian cancer. Some women may have radiotherapy. Targeted cancer drugs can help the body to control the growth of cancer cells. Occasionally doctors suggest radiotherapy for advanced ovarian cancer. Radiotherapy can shrink tumours and reduce symptoms.

""Advanced ovarian cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced ovarian cancer pipeline landscape is provided which includes the disease overview and Advanced ovarian cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced ovarian cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced ovarian cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced ovarian cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced ovarian cancer.
Advanced ovarian cancer Emerging Drugs Chapters

This segment of the Advanced ovarian cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced ovarian cancer Emerging Drugs
  • Oregovomab: OncoQuest
Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen.
  • Stenoparib: Allarity Therapeutics
Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.
  • DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2).

Further product details are provided in the report……..

Advanced ovarian cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced ovarian cancer drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Advanced ovarian cancer
There are approx. 50+ key companies which are developing the therapies for Advanced ovarian cancer. The companies which have their Advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.
  • Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced ovarian cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced ovarian cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced ovarian cancer drugs.

Advanced ovarian cancer Report Insights
  • Advanced ovarian cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Advanced ovarian cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Advanced ovarian cancer drugs?
  • How many Advanced ovarian cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced ovarian cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced ovarian cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced ovarian cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • OncoQuest
  • Allarity Therapeutics
  • AstraZeneca
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Ellipses Pharma
  • Merck KGaA
  • Pfizer
  • Jiangsu HengRui Medicine Co., Ltd.
  • Puma Biotechnology, Inc.
  • Bayer
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Daiichi Sankyo, Inc.
  • Astellas Pharma Inc
Key Products
  • Oregovomab
  • Stenoparib
  • Durvalumab
  • SC10914
  • DP303c
  • EP0057
  • Avelumab
  • Talazoparib
  • Apatinib
  • Neratinib
  • BAY1895344
  • TQ-B3525
  • DS-6000a
  • Enzalutamide

Table of Contents

210 Pages
Introduction
Executive Summary
Advanced ovarian cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced ovarian cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced ovarian cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Advanced ovarian cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Oregovomab: OncoQuest
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Stenoparib - Allarity Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
DS-6000a: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced ovarian cancer Key Companies
Advanced ovarian cancer Key Products
Advanced ovarian cancer- Unmet Needs
Advanced ovarian cancer- Market Drivers and Barriers
Advanced ovarian cancer- Future Perspectives and Conclusion
Advanced ovarian cancer Analyst Views
Advanced ovarian cancer Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us